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ABSTRACT 
Heroin addiction is a severe relapsing brain disorder associated with impaired cognitive con-
trol, including deficits in attention allocation. The thalamus has a high density of opiate recep-
tors and is critically involved in orchestrating cortical activity during cognitive control. How-
ever, there have been no studies on how acute heroin treatment modulates thalamic activity. 
In a cross-over, double-blind, vehicle-controlled study, 29 heroin-maintained outpatients were 
studied after heroin and placebo administration, while 20 healthy controls were included for 
the placebo condition only. Resting-state functional magnetic resonance imaging was used to 
analyse functional integration of the thalamus by three different resting state analysis tech-
niques. Thalamocortical functional connectivity (FC) was analysed by seed-based correlation, 
while intrinsic thalamic oscillation was assessed by analysis of regional homogeneity (ReHo) 
and the fractional amplitude of low frequency fluctuations (fALFF). Relative to the placebo 
treatment and healthy controls, acute heroin administration reduced thalamocortical FC to 
cortical regions, including the frontal cortex, while the reductions in FC to the mediofrontal 
cortex, orbitofrontal cortex and frontal pole were positively correlated with the plasma level 
of morphine, the main psychoactive metabolite of heroin. Furthermore, heroin treatment was 
associated with increased thalamic ReHo and fALFF values, whereas fALFF following heroin 
exposure correlated negatively with scores of attentional control. The heroin-associated in-
crease in fALFF was mainly dominated by slow-4 (0.027-0.073 Hz) oscillations. Our findings 
show that there are acute effects of heroin within the thalamocortical system and may shed 
new light on the role of the thalamus in cognitive control in heroin addiction. Future research 
is needed to determine the underlying physiological mechanisms and their role in heroin ad-
diction. 
Keywords: heroin addiction; heroin effects; thalamus; cognitive control; resting state; func-
tional connectivity 
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INTRODUCTION 
Loss of cognitive control, including compromised ability to inhibit impulsive drug-driven 
behaviour, is a key hallmark of drug addiction (Perry and Carroll, 2008). For example, it has 
been shown that heroin addicts have a significantly lower degree of impulse control than 
normal controls (Lee and Pau, 2002) and have difficulties in shifting attention from one sub-
ject to another (Ornstein, et al., 2000). Such deficits in selective attention and impulsivity are 
common in opiate-dependent patients (Bracken, et al., 2012; King, et al., 1999), and even per-
sist in abstinence after stopping a maintenance treatment (Prosser, et al., 2009). On the other 
hand, regular maintenance treatment may improve cognitive performance in heroin addicts, 
including attention and executive function (Wang, et al., 2014). 
Neuroimaging studies have indicated that impaired cognitive control in heroin addicts may 
arise from abnormal prefrontal brain activity (Pau, et al., 2002), in particular from the inferior 
frontal gyrus (IFG) (Fu, et al., 2008a; Lee, et al., 2005). Besides prefrontal brain regions, the 
thalamus is critically implicated in cognitive control and plays a core role in processing and 
maintaining attention (de Bourbon-Teles, et al., 2014; Lawrence, et al., 2003). There is evi-
dence that the effects of heroin are mostly mediated by µ receptors, which are densest in the 
cingulate gyrus, ventral tegmental area, cerebellum, thalamus, and hypothalamus (Maurer, et 
al., 1983; Pfeiffer, et al., 1982). Within the thalamus, µ receptors are densest within the dor-
somedial, lateroposterior and laterodorsal thalamic nucleus, as shown by in situ hybridisation 
in post-mortem studies of humans (Peckys and Landwehrmeyer, 1999). Given the high densi-
ty of opiate receptors in the thalamus (Apkarian, et al., 2005; Lever, 2007), the reduced glu-
cose metabolism in patients in a methadone maintenance program (Galynker, et al., 2000; 
Prosser, et al., 2009) and the decreased regional homogeneity in the resting state thalamus 
(ReHo) in chronic heroin addicts (Qiu, et al., 2011), it is conceivable that acute heroin use is 
associated with abnormal thalamic activity. 
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However, it is also becoming increasingly apparent that complex psychological processes, 
such as cognitive control, result from interactions between different brain regions rather than 
from local activity per se. Within this perspective, the thalamocortical system has an im-
portant role in synchronising the activities of thalamic and cortical neurons and is thus essen-
tial in orchestrating and integrating function across different brain regions (Jones, 2002; 
Steriade, 2006). A critical point is that the thalamus and cortical areas are functionally con-
nected during cognitive control (Aron and Poldrack, 2006). This evidence suggests that im-
paired cognitive control in heroin addiction might result not only from abnormal task-
associated activity in the IFG (Fu, et al., 2008a; Lee, et al., 2005), but also from disrupted 
thalamocortical connectivity. 
We have now carried out a cross-over, double-blind and vehicle-controlled study in a clinical 
sample of heroin-maintained patients, in which we used resting state functional magnetic res-
onance imaging (fMRI) to explore how heroin acutely modulates the functional integration of 
the thalamic system. Resting state fMRI provides a useful tool to study functional integration 
of brain regions, at the level of large scale neural systems, by analysis of low frequency fluc-
tuations in the blood oxygen level-dependent (BOLD) signal (Friston, 2009). We computed 
thalamocortical functional connectivity (FC) using a seed-based correlation approach (Biswal, 
et al., 1995), whereas local thalamic low frequency oscillation characteristics were assessed 
by analysis of ReHo and the fractional amplitude of low frequency fluctuations (fALFF). We 
expected that acute heroin administration would modulate thalamic functional integration 
during resting state oscillation. 
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METHODS 
Subjects 
This study was carried out with two group of subjects. 29 heroin-maintained outpatients (19 
male) were recruited from the Centre of Substance Use Disorders of the Psychiatric Universi-
ty Hospital of Basel. Inclusion criteria were age older than 18 years, past history of illicit in-
travenous heroin consumption, and participation in the heroin-assisted treatment for at least 6 
months with an unchanged heroin dose during the previous 3 months. In addition, 20 healthy 
controls were recruited from the general population in the same geographical area as the pa-
tients. Both subject groups were carefully screened, using a semi-structured clinical interview. 
The exclusion criteria were a positive alcohol breathalyser test, an additional physical disease, 
or a comorbid psychiatric disorder. Controls and patients were told to abstain from illicit drug 
consumption for the duration of the study, as well as to abstain from alcohol intake for 72 
hours and from smoking for 2 hours. Nevertheless, 15 patients were tested positive for co-
caine and 9 patients and 5 healthy controls for cannabis at one or both points of the measure-
ments. The subjects’ characteristics are summarised in Table 1. 
The study was approved by the local ethics committee and registered with 
http://clinicaltrials.gov (ID NCT01174927). After receiving a written and oral description of 
the aim of this study, all participants gave written informed consent statements before inclu-
sion. 
Experimental design 
The study was performed using a cross-over, double-blind and placebo-controlled design with 
two temporally distinct examination sessions; there was high overlap in used patients with 
previously published studies which resulted from the same examination (the procedure and 
healthy controls were always the same) (Schmidt, et al., 2014; Schmidt, et al., 2013a; 
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Schmidt, et al., 2013b; Schmidt e, et al., 2015; Walter, et al., 2014). All studies derived from 
theHeroin (Diaphin®) and placebo (saline solution) were administered intravenously through 
an indwelling intravenous catheter over a period of 30 seconds, as recently described (Walter, 
et al., 2014). During both sessions (with a time interval of about two weeks), patients received 
both heroin and placebo. The subjects who received heroin before scanning were administered 
vehicle after scanning (i.e., 60 min after the first injection), whereas the subjects who received 
placebo before scanning were administered heroin after scanning. The order was randomised 
in a balanced manner and did not affect the findings obtained. The administered heroin dose 
was equivalent to the subjects' individual dose. Healthy controls received only a placebo ad-
ministration and were examined only once.   
Bioanalytical and behavioural measurements 
Data on plasma levels have recently been published elsewhere (Walter, et al., 2014; Walter, et 
al., 2013). As we used the mean peak levels for later correlation analyses, we provide a brief 
summary of the analytical method. Plasma levels of diacetylmorphine (heroin) and morphine 
were quantified in venous ammonium heparinised plasma by high performance liquid chro-
matography on a 125×2 mm i.d. Nucleosil 50 C-8 ec column with a particle size of 5 µm and 
a 8×3 mm i.d. precolumn packed with Nucleosil 120 C-8 and a particle size of 3 µm, followed 
by diode array detection. The sample preparation and instrumental conditions were as previ-
ously described in detail (Bourquin D, et al., 1999). Plasma drug levels were measured three 
times, at 3, 10 and 60 minutes after drug injection. Individual peak concentrations of diace-
tylmorphine and morphine (the main psychoactive metabolite of diacetylmorphine) were used 
for further correlation analysis. 
Attention was assessed using the 30-item self-report questionnaire of the Barratt Impulsive-
ness Scale (BIS) (Patton, et al., 1995). Healthy controls and patients completed the question-
naire after receiving the treatment and before the scan. Patients completed the questionnaire in 
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both examination sessions. The BIS questionnaire assesses 6 first order and 3 second order 
factors of impulsivity, including attention, motor, and non-planning categories, as well as a 
total impulsivity score. Given the key role of the thalamus in attentional control (de Bourbon-
Teles, et al., 2014), only first  and second order attention scores were used for subsequent 
correlation analyses. The values of the first order attention scores range from 5 to 20, where a 
higher score implies worse attentional control. The second order attention score includes the 
first order score and scores for cognitive instability, with a range from 8 to 32. 
Image acquisition 
Scanning was performed on a 3 Tesla scanner (Magnetom Verio, Siemens Healthcare, Erlan-
gen, Germany). A 5 minutes resting state condition (20 minutes after substance administra-
tion) was examined with a whole brain echo planar imaging (EPI) sequence (TR = 2000 ms, 
TE = 28 ms, flip angle = 82°, field of view = 228×228 mm2, 32 slices, voxel size = 
3.6×3.6×3.8 mm3). In total, 152 EPI volumes were acquired. In addition, images were ac-
quired with a high resolution T1-weighted magnetisation-prepared rapid acquisition gradient 
echo (MPRAGE) image (TR = 2000 ms; TE = 3.37 ms; flip angle = 8°; inversion time = 1000 
ms; 176 slices; slice thickness = 1 mm; voxel size = 1×1×1 mm3).  
Image preprocessing 
EPI volumes were preprocessed using statistical parametric mapping software (SPM8; 
http://www.fil.ion.ucl.ac.uk/spm/software/spm8/). EPI volumes of each scanning session were 
realigned using rigid transformation, normalised by linear and nonlinear transformation into 
MNI space (Montreal Neurological Institute), by using the ICBM152 template (International 
Consortium for Brain Mapping), spatially smoothed with a 6 mm full width half maximum 
(FWHM) Gaussian kernel, and band-pass filtered for the frequency range of 0.01-0.08 Hz. 
Thalamocortical connectivity (seed-based correlation) 
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Functional data were analysed using the seed-driven approach of the CONN toolbox (CONN 
13.1; http://web.mit.edu/swg/software.htm) (Whitfield-Gabrieli and Nieto-Castanon, 2012). 
We defined the bilateral thalamus as seed region of interest for the between-group (patients 
and controls) and the between-treatment (placebo and heroin) analyses. In order to understand 
between-treatment differences in more detail, we additionally performed analyses with seeds 
of the bilateral medial dorsal, lateral posterior and lateral dorsal thalamic nucleus, which are 
known to show high µ receptor density (Peckys and Landwehrmeyer, 1999). The masks were 
generated by WFU PickAtlas (Maldjian, et al., 2003). Preprocessed and band-pass-filtered 
EPI volumes were used for computation of seed-to-voxel FC maps. The correlation coeffi-
cients between the signal within the thalamic seed and the signal of all other brain voxels 
were estimated. Confounding signals related to white matter and cerebrospinal fluid were re-
moved through linear regression. Realignment parameters (six dimensions with first order 
derivative) were defined as first level covariates. 
Thalamic regional homogeneity (ReHo) 
For each subject and treatment, ReHo maps were computed using Kendall’s coefficient of 
concordance (KCC), as integrated in the REST toolkit (REST 1.8; http://www.restfmri.net) 
(Song, et al., 2011). The BOLD time course in preprocessed normalised non-smoothed EPI 
volumes was corrected for linear trends and a temporal band-pass filter of 0.01-0.08 Hz was 
applied. KCC was calculated for each voxel time series, in order to measure the similarity of 
the ranked time series with its 26 neighbour voxels. The resulting KCC-ReHo maps were 
standardised by dividing each voxel by the global mean within a whole brain mask and 
smoothed with a 6 mm FWHM Gaussian kernel. 
Thalamic fractional amplitude of low frequency fluctuations (fALFF) 
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Preprocessed normalised and non-smoothed EPI volumes were used to compute fALFF maps 
with the REST toolkit (Song, et al., 2011). The frequency-filtered time series of each voxel 
are described by a Fourier series, where the BOLD signal is expressed as a sum of sines and 
cosines (Davis, 1989). The ALFF value is the averaged square root of the power spectrum 
obtained via fast Fourier transformation, whereas fALFF values reflect the ratio of the power 
spectrum of the signal (0.01-0.08 Hz) to that of the entire frequency range (Zou, et al., 2008). 
As categorised in previous research, we also compared thalamic frequency between heroin 
and placebo treatment by preprocessing and reanalysing data using slow-4 (0.027-0.073 Hz) 
and slow-5 (0.01-0.027 Hz) frequency bands (Buzsaki and Draguhn, 2004; Zhang, et al., 
2015; Zou, et al., 2008). The computed fALFF maps were standardised by dividing each 
voxel by the global mean within a whole brain mask and smoothed with a 6 mm FWHM 
Gaussian kernel. 
Computation of treatment difference maps 
We used the image calculation function implemented in SPM8 to compute difference maps 
between the placebo and heroin treatment. Treatment-related changes in thalamocortical FC 
(magnitude of correlation coefficient) were computed by subtracting the placebo from the 
heroin treatment. To investigate only LFF values of positive functional connectivity we de-
cide to exclude all negative values within the placebo and heroin treatment. Treatment-
associated differences in ReHo and fALFF values were computed by subtracting heroin from 
placebo maps. 
Statistical analysis 
Between-group and between-treatment analyses were performed using a general linear model 
(GLM) in SPM8. Seed-based thalamic FC, ReHo and fALFF maps were tested by voxelwise 
whole brain analysis. Paired t tests were used to test between-treatment differences in patients 
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a n d t w o s a m pl e t t ests w er e us e d t o t est diff er e n c es b et w e e n p ati e nts a n d h e alt h y c o ntr ols. 
Tr e at m e nt diff er e n c e m a ps of t h al a m o c orti c al F C, R e H o a n d f A L F F w er e us e d f or w h ol e 
br ai n c orr el ati o n a n al ys e s wit h p e a k pl as m a l e v els of m or p hi n e. First a n d s e c o n d or d er BI S 
att e nti o n s c or es w er e us e d s e p ar at el y f or t h e c orr el ati o n a n al ysis wit h t h al a m o c orti c al F C, 
R e H o a n d f A L F F m a ps aft er t h e pl a c e b o a n d h er oi n a d mi nistr ati o n i n h er oi n- d e p e n d e nt p a-
ti e nts. All a n al ys es w er e p erf or m e d usi n g a cl u st er-l e v el i nf er e n c e str at e g y wit h a cl ust er-
f or mi n g t hr es h ol d of p < 0. 0 0 1 a n d a dj ust e d f or f a mil y- wis e err or ( F W E) at p < 0. 0 5 
( H a y as a k a, et al., 2 0 0 4). F or c orr el ati o n a n al ys es, w e us e d a bi n ar y m as k of m ai n tr e at m e nt 
diff er e n c es wit h a cl ust er-f or mi n g t hr es h ol d of p < 0. 0 5 a n d a dj ust e d f or f a mil y- wis e err or 
( F W E) at p < 0. 0 5. St atisti c al c o m p aris o ns of d e m o gr a p hi c a n d cli ni c al c h ar a ct eristi cs w er e 
p erf or m e d wit h S P S S 1 9 (I B M S P S S St atisti cs; Ar m o n k, N Y: I B M C or p) usi n g i n d e p e n d e nt 
s a m pl e  t  t ests  f or  p ar a m etri c  a n d χ 2  t ests  f or  n o n p ar a m etri c  d at a.
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RESULTS 
Demographic and clinical characteristics 
The groups of patients and controls did not differ in age, gender or cannabis use. Patients con-
sumed significantly more cocaine, more cigarettes per day and were less often employed than 
controls. The demographic and clinical characteristics of the study sample are summarised in 
Table 1. 
Bioanalytical and behavioural measurements 
The mean plasma peak level of diacetylmorphine was 1042.4 ng/ml and ranged from 40 to 
3051 ng/ml. Morphine concentrations showed a mean peak of 976.6 ng/ml and ranged from 
39 to 3885 ng/ml. The results on drug plasma levels and their temporal decay have been pre-
viously described in more detail (Walter, et al., 2014). Peak plasma levels of diacetylmor-
phine (p = 0.343, r = 0.203) and morphine (p = 0.863, r = -0.037) did not correlate significant-
ly with daily heroin dose.  
No significant differences in BIS total score (p = 0.209, t = 1.286), or first order (p = 0.332,   t 
= 0.987) or second order attention scores (p = 0.124, t = 1.586) were found after heroin and 
placebo treatment in patients. Relative to healthy controls, patients after heroin treatment 
showed significantly higher BIS total scores (p = 0.013, t = 2.568), and first order (p = 0.001, 
t = 4.164), and second order attention scores (p = 0.011, t = 2.636) (Table 1). After placebo 
treatment, patients showed significantly higher BIS total scores (p = 0-003, t = 3.115), first 
order (p < 0.001, t = 4.079), and second order attention scores (p = 0.002, t = 3.246) in com-
parison to healthy controls. 
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Thalamocortical connectivity (seed-based correlation analysis) 
In comparison to placebo, heroin in patients reduced thalamic FC to the bi-hemispherical 
frontal, parietal and temporal regions and increased thalamus FC (Figure 1, Table 2). Heroin 
also reduced thalamic FC to parietal, temporal and occipital regions relative to healthy con-
trols, whereas no heroin-induced increase was found. After placebo administration, patients 
showed reduced thalamic FC to the temporal gyrus compared with healthy controls. 
Analyses of FC of specific thalamic nuclei in patients revealed a heroin-associated reduction 
in connectivity strength between the precentral gyrus and the lateral dorsal nucleus. The lat-
eral posterior nucleus was instead associated with increased connectivity strength within the 
thalamus during heroin treatment. The medial dorsal nucleus was associated with the broadest 
heroin-associated reduction in connectivity strength, including the temporal, parietal, occipital 
and frontal lobe (Table 3). 
Thalamic regional homogeneity (ReHo) 
Between-treatment analysis of ReHo revealed that heroin treatment in patients significantly 
increased values in the bilateral thalamus, posterior cingulate, postcentral and precentral gy-
rus, compared with the placebo treatment (Figure 3, Table 4). In comparison to heroin treat-
ment, increased ReHo values were found during placebo in the temporal, frontal and occipital 
cortex. In comparison to heroin treatment, healthy controls showed increased ReHo values in 
the frontal cortex. 
Thalamic fractional amplitude of low frequency fluctuations (fALFF) 
Between-treatment analysis of fALFF in patients revealed increased values for heroin treat-
ment within the precentral gyrus and the thalamus relative to the placebo treatment (Figure 32 
Table 5). Healthy controls showed increased fALFF values in the precuneus and posterior 
cingulate gyrus and decreased fALFF values in the cerebellum, midbrain and amygdala in 
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comparison to the heroin treatment. Placebo treatment in patients was associated with in-
creased fALFF values in the cerebellum, inferior temporal and parahippocampal gyrus.  
In depth analysis of slow-4 and slow-5 frequency bands within patients revealed increased 
slow-5 fALFF values in the precentral gyrus during heroin treatment. Slow-4 fALFF was as-
sociated with increased values in the bilateral thalamus during heroin treatment (Table 6). 
Correlation analyses 
Correlation analyses showed that peak plasma levels of morphine correlated positively with 
heroin-induced reduction in thalamic FC to the frontal orbital cortex, mediofrontal cortex and 
frontal pole (Table 7). By analysing heroin and placebo treatment separately, we found a neg-
ative correlation between first-order attention score of BIS (heroin treatment) and fALFF val-
ues (heroin treatment), within a cluster including the thalamus, midbrain and hypothalamus 
(Table 8, Figure 3). No correlation was found between first  and second order attention scores 
of BIS and treatment-dependent thalamocortical FC and ReHo. 
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DISCUSSION 
In this study, we investigated whether acute heroin treatment leads to alterations in spontane-
ous neural activity within the thalamocortical system. We performed three different resting 
state analyses to detect modulations of functional integration and segregation of thalamic low 
frequency oscillation and examined whether these effects were related to clinical characteris-
tics and behavioural indices of attention. We could show that, in comparison to placebo 
treatment and healthy controls, heroin acutely reduced thalamocortical FC to multiple cortical 
regions, including parts of the frontal cortex. The heroin-induced reductions in FC from the 
thalamus to the mediofrontal cortex, orbitofrontal cortex and frontal pole were positively cor-
related with plasma levels of morphine. Furthermore, and in contrast to reductions in thalamic 
FC, we found increased thalamic ReHo and fALFF values during heroin treatment. The hero-
in-associated increase in fALFF values were driven by alterations in the slow-4 oscillation 
band. Plasma levels of heroin were positively correlated with treatment differences in fALFF 
in the bilateral lateral occipital cortex, while fALFF within the right thalamus correlated nega-
tively with attention scores measured by BIS. 
Impaired cognitive control plays an important role in the compulsive and drug-seeking behav-
iour of drug-dependent subjects (Perry and Carroll, 2008). It has repeatedly been shown that 
this deficit in cognitive functioning in heroin addicted individuals is accompanied by reduced 
activity in the right IFG and ACC (Fu, et al., 2008b; Lee, et al., 2005). Our group has recently 
extended these findings by showing that acute heroin administration not only impairs cogni-
tive control by reducing IFG and ACC activity in heroin-dependent patients, but also effective 
connectivity from the ACC to the IFG during a cued Go/No-Go task (Schmidt, et al., 2014; 
Schmidt, et al., 2013b). However, besides the crucial interplay between the dorsal ACC and 
IFG, the IFG is also functionally connected with the thalamus during cognitive functioning 
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(i.e. response inhibition) (Aron and Poldrack, 2006). In the present study, we found that acute 
heroin treatment reduced FC between the thalamus and frontal brain regions, which suggests 
that these reductions may modulate cognitive functioning in heroin-dependent subjects. This 
finding adds to our previous results that acute heroin administration not only reduces ACC 
activity and its connectivity to the IFG (Schmidt, et al., 2014; Schmidt, et al., 2013a), but also 
the connectivity from the thalamus to the frontal cortex. The reduced thalamocortical FC after 
heroin treatment may be regarded as desynchronised activity between the thalamus and the 
cortex and may contribute to impairment in the alerting attention network. Heroin-associated 
reduction in frontal perfusion and gray matter volume, as shown in our previous studies 
(Denier, et al., 2013a; Denier, et al., 2013b), may be associated with reduction in thalamofron-
tal FC. 
In contrast to the heroin-induced reduction in thalamocortical FC, we found enhancement of 
local thalamic parameters, including fALFF and ReHo values. While resting state FC can be 
taken as a measure of coupling in oscillation between distant regions, ALFF/fALFF measures 
reflect the extent of BOLD-associated spontaneous oscillation and so indirectly its neural ac-
tivity (Duff, et al., 2008; Fransson, 2006). ReHo is a good index of local integrity as assessed 
by oscillation synchronisation (Zang, et al., 2004). However, the direct relationships of the 
three parameters, FC, fALFF and ReHo, are not yet fully understood. There are only two stud-
ies examining long term ALFF changes in heroin addicts, but no ALFF changes were found in 
the thalamus. Compared to healthy controls, heroin addicts showed decreased ALFF values in 
the temporal and frontal lobe, including the orbitofrontal cortex and the ACC. Moreover, her-
oin addicts showed decreased ALFF in the right caudate that correlated with the duration of 
heroin use (Wang, et al., 2013). A previous study in heroin-dependent individuals showed 
decreased ReHo values in the thalamus relative to healthy controls (Qiu, et al., 2011). This 
discrepancy may result from differences in the included patient samples, such as differences 
in the durations of heroin use, duration of maintenance treatment or dose of maintenance 
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treatment. Furthermore, the placebo treatment in our study may induced a state of heroin 
withdrawal (Schmidt, et al., 2013a), resulting in a different psychological state from that of 
the patients in Qiu et al. (2011). However, despite this discrepancy, the authors concluded that 
this decrease in the ReHo values in the bilateral medial dorsal nucleus might mediate the at-
tention deficits in chronic heroin users. In accordance with such an interpretation, we could 
show that fALFF values in the right thalamus after heroin treatment were negatively correlat-
ed with subjective scores on attentional control. This corresponds with a previous study show-
ing a negative correlation between attentional BIS scores in codeine-dependent subjects and 
ReHo values in the thalamus (Qiu, et al., 2013) as ReHo and fALFF values are known to be 
correlated. More work is needed to understand the relation between thalamic ReHo and ALFF 
alteration and attentional control. 
Opioid-associated alterations in thalamic functionality are well documented in animals. In 
particular, Brunton and Charpak showed that a systemically administered µ-opioid agonist 
inhibited the entire thalamus by inducing hyperpolarisation and shifting thalamic cell firing 
from the tonic to the bursting mode (Brunton and Charpak, 1998). The burst firing mode is 
characteristic of thalamic relay neurons (Jahnsen and Llinas, 1984) and plays an important 
role in slow wave sleep and drowsiness (Livingstone and Hubel, 1981; Steriade, et al., 1993). 
We may speculate that our findings of heroin-induced reduction in thalamocortical FC and 
enhancement of fALFF and ReHo reflect a shift towards the thalamic burst firing mode on a 
higher functional level. 
Some limitations need to be considered. Our patients were recruited from a population which 
mainly consisted of individuals with long standing polysubstance use, including cocaine con-
sumption. Although this problem is virtually inevitable when chronic heroin-dependent indi-
viduals are examined, cocaine and other drug use may have confounded our findings. Howev-
er, the greatest differences were found between heroin and placebo treatment within patients.  
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Another limitation is that BIS is not a direct psychometric measurement of attention and im-
pulsivity. Therefore the BIS scores are stable within patients, did not differ between treat-
ments, but may be substantially influenced by recurring heroin effects. A more direct cogni-
tive assessment of attention and impulsivity would help to clarify the acute modulation of 
heroin on attentional control functions and whether this effect is related to the reported altera-
tions in thalamic activities. 
In conclusion, our results showed that acute heroin administration leads to abnormalities in 
functional integration and segregation of thalamic resting-state oscillation. Abnormalities 
were partially related to clinical characteristics and plasma levels of morphine. Reduced 
thalamocortical FC and altered intrinsic thalamic oscillation characteristics may explain some 
deficits in cognitive functioning in heroin-dependent patients. Further research is needed to 
elucidate the relationship between thalamic function and cognitive control in heroin addiction. 
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Figure legends 
Figure 1: Thalamocortical FC differences between heroin and placebo treatment in heroin-
dependent patients. Red indicates increased FC by heroin and blue indicates reduced FC rela-
tive to the placebo treatment. 
Figure 2: Significant positive relation of the heroin-induced reduction in thalamic FC to the 
left (128 voxels) and right orbitofrontal cortex (65 voxels) and the left frontal pole (173 
voxels) with the peak plasma levels of morphine. 
Figure 3: Significant increase in thalamic ReHo and fALFF values induced by acute heroin 
compared with placebo treatment. Spectral colours indicate mean thalamic ReHo and fALFF 
values of heroin and placebo treatment. 
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Table 2: Resting-state associated thalamocortical functional connectivity (FC) 
Brain region 
Cluster size 
(voxels) 
Cluster p-value 
(FWE corrected) 
MNI coordinats 
(x y z) 
Hemisphere 
Z-value at 
voxel level 
Heroin > Placebo Treatment 
Thalamus 174 0.007 -16 -16 6 L 5.07 
   -2 -24 4 L 3.53 
Thalamus 117 0.048 6 -14 4 R 3.94 
   12 -20 12 R 3.61 
Heroin < Placebo Treatment 
Precuneus 495 < 0.001 10 -52 34 R 4.68 
   6 -62 28 R 4.05 
   12 -52 42 R 4.04 
Lateral Occipital Cortex 159 0.012 48 -66 26 R 4.29 
Middle Temporal Gyrus 165 0.01 58 -6 -26 R 4.24 
   60 -4 -12 R 4.00 
   58 -12 -18 R 3.82 
Precuneus 195 0.004 -8 -66 14 L 4.12 
   -4 -54 14 L 3.42 
Medial Frontal Gyrus 118 0.046 14 48 12 R 4.11 
   6 54 8 R 3.50 
   -2 50 10 L 3.44 
Superior Parietal Lobule 119 0.045 -22 -54 66 L 4.04 
Controls > Heroin Treatment 
Middle Temporal Gyrus 507 < 0.001 58 -6 -20 R 5.00 
   50 2 -32 R 4.03 
   64 -24 -20 R 3.91 
Precentral Gyrus 162 0.025 16 -18 72 R 4.68 
   14 -24 66 R 3.82 
   10 -18 54 R 3.68 
Lateral Occipital Cortex 349 < 0.001 50 -62 28 R 4.60 
   56 -54 22 R 4.36 
Middle Temporal Gyrus 156 0.03 -64 -8 -26 L 4.51 
Precuneus 1380 < 0.001 0 -54 8 R 4.48 
   18 -50 40 R 4.35 
   14 -40 4 R 4.26 
Controls < Heroin Treatment 
none      
Controls > Placebo Treatment  
Inferior Temporal Gyrus 237 0.004 -52 -30 -28 L 4.09 
   -62 -26 -30 L 3.96 
   -50 -40 -28 L 3.80 
Controls < Placebo Treatment 
none      
FWE: family-wise error; L: left; R: right.  
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Table 3: Resting-state associated functional connectivity (FC)of specific thalamic nuclei. 
Brain region 
Cluster size 
(voxels) 
Cluster p-value 
(FWE corrected) 
MNI coordinats 
(x y z) 
Hemisphere 
Z-value at 
voxel level 
Lateral Dorsal Nucleus: Heroin < Placebo Treatment 
Precentral Gyrus 141 0.019 -12 -26 80 L 4.90 
Precentral Gyrus   -20 -24 78 L 4.04 
Precentral Gyrus   -22 -18 72 L 3.27 
Lateral Dorsal Nucleus: Heroin > Placebo Treatment 
none      
Lateral Posterior Nucleus: Heroin < Placebo Treatment 
none      
Lateral Posterior Nucleus: Heroin > Placebo Treatment 
Thalamus 211 0.003 -10 -16 6 L 4.45 
Thalamus   -16 -24 8 L 4.18 
Thalamus   -6 -24 8 L 372 
Thalamus 125 0.038 12 -10 8 R 4.39 
Medial Dorsal Nucleus: Heroin < Placebo Treatment 
Postcentral Gyrus 2194 < 0.001 -32 -30 52 L 4.99 
Postcentral Gyrus   -50 -20 52 L 4.77 
Precentral Gyrus   -12 -16 80 L 4.47 
Middle Temporal Gyrus 764 < 0.001 58 -6 -24 R 4.89 
Superior Temporal Gyrus   58 -4 -12 R 4.72 
Middle Temporal Gyrus   58 -14 -16 R 4.67 
Precentral Gyrus 1156 < 0.001 10 -20 80 R 4.64 
Postcentral Gyrus   46 -26 58 R 4.60 
Postcentral Gyrus   20 -36 54 R 4.40 
Parahippocampal Gyrus 254 0.001 24 -16 -26 R 4.60 
Parahippocampal Gyrus   28 -24 -16 R 4.44 
Parahippocampal Gyrus   26 -34 -16 R 4.31 
Precuneus 2045 < 0.001 10 -60 26 R 4.59 
Precuneus   10 -54 34 R 4.52 
Cerebellum   -24 -48 -22 L 4.51 
Lateral Occipital Cortex 242 0.001 48 -68 26 R 4.38 
Angular Gyrus   54 -58 34 R 3.22 
Lateral Occipital Cortex 296 < 0.001 -46 -70 12 L 4.32 
Angular Gyrus   -50 -50 22 L 4.17 
Cerebellum   -52 -64 26 L 3.58 
Parahippocampal Gyrus 149 0.017 -20 -14 -26 L 4.29 
Parahippocampal Gyrus   -30 -26 -22 L 3.82 
Temporal Fusiform Cortex   -30 -32 -28 L 3.64 
Superior Frontal Gyrus 151 0.016 20 22 50 R 4.24 
Middle Frontal Gyrus   30 34 46 R 3.20 
Superior Frontal Gyrus 175 0.008 -58 -36 -4 L 4.18 
Middle Frontal Gyrus   -52 -36 -10 L 4.11 
Precentral Gyrus 183 0.006 -4 -20 54 L 4.07 
Precentral Gyrus   0 -18 64 R 3.74 
Precentral Gyrus   12 -16 58 R 3.57 
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Occipital Fusiform Gyrus 206 0.003 12 -90 -16 R 4.07 
Lingual Gyrus   -4 -88 -8 L 3.90 
Occipital Pole   4 -94 -4 R 3.74 
Medial Dorsal Nucleus: Heroin > Placebo Treatment 
Thalamus 216 0.002 -14 -14 4 L 4.73 
Thalamus   -10 -18 10 L 4.71 
Thalamus   -2 -24 4 L 3.71 
Thalamus 135 0.027 12 -18 12 R 4.33 
Thalamus   10 -8 2 R 3.00 
FWE: family-wise error; L: left; R: right. 
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Table 4: Resting-state associated regional homogeneity (ReHo) 
Brain region 
Cluster size 
(voxels) 
Cluster p-value 
(FWE corrected) 
MNI coordinats 
(x y z) 
Hemisphere 
Z-value at 
voxel level 
Heroin > Placebo Treatment 
Posterior Cingulate Gyrus 639 < 0.001 2 -28 30 R 5.84 
Posterior Cingulate Gyrus   -4 -44 12 L 3.30 
Thalamus 1286 < 0.001 -10 -14 12 L 5.38 
Thalamus   6 -8 4 R 5.33 
Thalamus   -18 -34 12 L 4.83 
Postcentral Gyrus 831 < 0.001 2 -38 62 R 4.66 
Precentral Gyrus   0 -28 60 R 4.63 
Precentral Gyrus   2 -20 70 R 4.50 
Heroin < Placebo Treatment 
Temporal Pole 414 0.006 -50 2 -34 L 4.76 
Inferior Temporal Gyrus   -56 -16 -26 L 4.17 
Middle Temporal Gyrus   -58 -2 -26 L 4.01 
Superior Frontal Gyrus 381 0.009 14 32 62 R 4.62 
Middle Frontal Gyrus   38 22 58 R 4.29 
Middle Frontal Gyrus   28 34 52 R 4.06 
Lateral Occipital Cortex 401 0.007 -36 -90 22 L 4.25 
Lateral Occipital Cortex   -36 -80 42 L 4.22 
Lateral Occipital Cortex   -48 -78 24 L 4.04 
Controls > Heroin Treatment 
Frontal Pole 259 0.039 20 56 30 R 6.12 
Superior Frontal Gyrus   10 52 24 R 5.41 
Frontal Pole   6 58 28 R 4.75 
Middle Frontal Gyrus 299 0.021 -36 22 56 L 4.53 
Middle Frontal Gyrus   -44 20 48 L 4.29 
Superior Frontal Gyrus   -18 30 52 L 4.19 
Controls < Heroin Treatment 
none      
Controls > Placebo Treatment 
none      
Controls < Placebo Treatment 
none      
FWE: family-wise error; L: left; R: right. 
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Table 5: Resting-state associated fractional amplitude of low frequency fluctuations (fALFF) 
Brain region 
Cluster size 
(voxels) 
Cluster p-value 
(FWE corrected) 
MNI coordinats 
(x y z) 
Hemisphere 
Z-value at 
voxel level 
Heroin > Placebo Treatment 
Precentral Gyrus 540 0.001 2 -32 60 R 6.06 
Precentral Gyrus   2 -22 68 R 5.62 
Precentral Gyrus   -4 -26 54 L 3.93 
Thalamus 554 < 0.001 -12 -20 8 L 4.71 
Thalamus   -8 -12 8 L 4.67 
Thalamus   8 -8 4 R 4.53 
Heroin < Placebo Treatment 
none      
Controls > Heroin Treatment 
Posterior Cingulate Gyrus 563 0.001 -4 -50 32 L 5.13 
Precuneus   12 -58 26 R 4.90 
Precuneus   -10 -60 22 L 4.28 
Controls < Heroin Treatment 
Cerebellum 273 0.039 -30 -58 -26 L 4.59 
Cerebellum   -38 -58 -32 L 3.99 
Cerebelum   -48 -70 -30 L 3.54 
Midbrain 550 0.001 -10 -4 -10 L 4.37 
Amygdala   -26 -2 -18 L 4.20 
Midbrain   -14 -20 -14 L 3.81 
Controls > Placebo Treatment 
none      
Controls < Placebo Treatment 
Cerebellum 310 0.024 28 -34 -32 R 3.93 
Inferior Temporal Gyrus   46 -38 -24 R 3.69 
Parahippocampal Gyrus   26 -20 -30 R 3.38 
 
FWE: family-wise error; L: left; R: right.  
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Table 6: Differences in slow-5 and slow-4 amplitude of low frequency fluctuations (fALFF) 
bands in heroin and placebo treatment 
Brain region 
Cluster size 
(voxels) 
Cluster p-value 
(FWE corrected) 
MNI coordinats 
(x y z) 
Hemisphere 
Z-value at 
voxel level 
fALFF slow-5: Heroin > Placebo Treatment 
Precentral Gyrus 1305 < 0.001 2 -20 70 R 4.29 
Precentral Gyrus   20 -28 66 R 4.22 
Precentral Gyrus   6 -28 70 R 4.13 
fALFF slow-5: Heroin < Placebo Treatment 
none      
fALFF slow-4: Heroin > Placebo Treatment 
Thalamus 814 < 0.001 8 -8 4 R 4.96 
Thalamus   -8 -12 8 L 4.97 
Thalamus   8 -24 4 R 3.90 
fALFF slow-4: Heroin < Placebo Treatment 
none      
 
fALFF slow-4: 0.027-0.073 Hz; fALFF slow-5: 0.01-0.027 Hz;  FWE: family-wise error; L: left; R: right. 
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Table 7: Positive correlations of morphine metabolites and regional treatment difference val-
ues in thalamocortical functional connectivity (FC), regional homogeneity (ReHo) and frac-
tional amplitude of low frequency fluctuations (fALFF). 
Brain region 
Cluster size 
(voxels) 
Cluster p-value 
(FEW corrected) 
MNI coordi-
nates (x y z) 
Hemisphere 
Z-value at 
voxel level 
Thalamocortical FC and morphine plasma levels 
Frontal Orbital Cortex 52 0.046 -24 12 -20 L 5.41 
ReHo and morphine plasma levels 
none      
fALFF and morphine plasma levels 
none      
fALFF: fractional amplitude of low frequency fluctuations; FC: functional connectivity; FWE: family-wise error; L: left; R: 
right; ReHo: regional homogeneity. 
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Table 8: Negative correlation of first-order BIS attention score with fractional amplitude of 
low frequency fluctuations (fALFF). 
Brain region 
Cluster size 
(voxels) 
Cluster p-value 
(FWE corrected) 
MNI coordi-
nates (x y z) 
Hemisphere 
Z-value at 
voxel level 
fALFF (Heroin treatment) and first-order BIS 
Midbrain 238 0.049 4 -10 -14 R 4.20 
Thalamus   10 -16 -6 R 4.17 
Hypothalamus   8 -6 -8 R 3.34 
 
BIS: Barrett Impulsiveness Scale; fALFF: fractional amplitude of low frequency fluctuations; FWE: family-wise error; L: 
left; R: right; ReHo: regional homogeneity. 
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FIGURES 
Figure 1: Thalamocortical FC differences between heroin and placebo treatment in heroin-
dependent patients. Red indicates increased FC by heroin and blue indicates reduced FC rela-
tive to the placebo treatment. 
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Figure 2: Significant increase in ReHo and fALFF values induced by acute heroin compared 
with placebo treatment. Spectral colours indicate mean thalamic ReHo and fALFF values of 
heroin and placebo treatment. 
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Figure 3: Negative correlation of first-order BIS attention score with fractional amplitude of 
low frequency fluctuations (fALFF). The correlation plot is shown only for visualization pur-
pose and doesn’t represent statistical inference. 
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